Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae , Klebsiella aerogenes , Citrobacter freundii , Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients
Journal of Antimicrobial Chemotherapy · 03.04.2023 · 78 (4) · 1009-1014
DOI: 10.1093/jac/dkad037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 06.03.2023. Verfasst von Brian Lu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Stanford Health Care, 300 Pasteur Drive, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Enterobacter aerogenes, Morganella morganii, Bacteremia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The role of piperacillin/tazobactam for treatment of serious infections due to AmpC-producing organisms remains debatable, particularly in immunocompromised patients.
Methods
This was a retrospective cohort study in immunocompromised patients that investigated the effect of definitive treatment with either piperacillin/tazobactam versus cefepime or carbapenems for bacteraemia caused by cefoxitin-non-susceptible Enterobacterales. The primary endpoint was a composite of clinical and microbiological failure. A logistic regression model was constructed to assess the impact of definitive treatment choice on the primary endpoint.
Results
A total of 81 immunocompromised patients with blood cultures positive for cefoxitin-non-susceptible Enterobacterales were included for analysis. There was more microbiological failure in the piperacillin/tazobactam arm compared with the cefepime/carbapenem arm (11.4% versus 0.0%, P = 0.019). Definitive treatment with cefepime or a carbapenem was associated with a decreased odds of clinical or microbiological failure (OR 0.303, 95% CI 0.093–0.991, P = 0.048) when controlling for baseline characteristics.
Conclusions
In immunocompromised patients with bacteraemia due to cefoxitin-non-susceptible Enterobacterales, definitive treatment with piperacillin/tazobactam was associated with an increased risk of microbiological failure and higher odds of clinical or microbiological failure compared with cefepime or carbapenems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Stanford Health Care, 300 Pasteur Drive, Stanford, CA 94305, USA.
- Department of Quality, Patient Safety and Effectiveness, Stanford Health Care, Stanford, CA, USA.
- Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA.
- Division of Clinical Pharmacy, UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA.
- Division of Clinical Pathology, Stanford University School of Medicine, Stanford, CA, USA.
ORCID-Profile: Brian Lu
Zitieren
APA
Lu, B., Wong, M., Ha, D., Bounthavong, M., Banaei, N., Deresinski, S., & Diep, C. (2023). Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae , Klebsiella aerogenes , Citrobacter freundii , Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients. Journal of Antimicrobial Chemotherapy, 78(4), 1009-1014. https://doi.org/10.1093/jac/dkad037
Vancouver
Lu B, Wong M, Ha D, Bounthavong M, Banaei N, Deresinski S, et al. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae , Klebsiella aerogenes , Citrobacter freundii , Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients. Journal of Antimicrobial Chemotherapy. 2023;78(4):1009-1014. doi:10.1093/jac/dkad037
BibTeX
@article{Lu2023,
author = {Lu, Brian and Wong, Miranda and Ha, David and Bounthavong, Mark and Banaei, Niaz and Deresinski, Stanley and Diep, Calvin},
title = {Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae , Klebsiella aerogenes , Citrobacter freundii , Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {4},
pages = {1009--1014},
doi = {10.1093/jac/dkad037}
}
EUVIMED